TECHNOLOGY-BASED
pharmaceutical company Verseon
has announced that it has
developed a new class of oral,
highly selective, direct thrombin
inhibitors which have demonstrated
reduced risk of major bleeding in
comparison with current novel oral
anticoagulants (NOACs).
The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 14 Jan 16
To see the full story, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 14 Jan 16
